These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33950772)

  • 1. Assessing the pricing and benefits of oncology products: an update.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):335-342. PubMed ID: 33950772
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.
    Godman B; Hill A; Simoens S; Selke G; Selke Krulichová I; Zampirolli Dias C; Martin AP; Oortwijn W; Timoney A; Gustafsson LL; Voncina L; Kwon HY; Gulbinovic J; Gotham D; Wale J; Cristina Da Silva W; Bochenek T; Allocati E; Kurdi A; Ogunleye OO; Meyer JC; Hoxha I; Malaj A; Hierländer C; Sauermann R; Hamelinck W; Petrova G; Laius O; Langner I; Yfantopoulos J; Joppi R; Jakupi A; Greiciute-Kuprijanov I; Vella Bonanno P; Piepenbrink JH; de Valk V; Wladysiuk M; Marković-Peković V; Mardare I; Fürst J; Tomek D; Obach Cortadellas M; Zara C; Pontes C; McTaggart S; Laba TL; Melien Ø; Wong-Rieger D; Bae S; Hill R
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):527-540. PubMed ID: 33535841
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
    Frois C; Howe A; Jarvis J; Grice K; Wong K; Zacker C; Sasane R
    J Manag Care Spec Pharm; 2019 Feb; 25(2):246-259. PubMed ID: 30698093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
    Parmar A; Jiao T; Saluja R; Chan KKW
    Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Policy in Bulgaria.
    Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
    Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Market spiral pricing of cancer drugs.
    Light DW; Kantarjian H
    Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
    [No Abstract]   [Full Text] [Related]  

  • 7. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
    Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
    Usher C; Tilson L; Bennett K; Barry M
    Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seeking value as cancer drug costs soar.
    Bender E
    Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
    Persson U; Norlin JM
    Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost of medications in the oncology sector in the context of health economics].
    Walter E; Batista A
    Wien Med Wochenschr; 2008; 158(7-8):227-33. PubMed ID: 18500477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?
    McGuire A; Drummond M; Martin M; Justo N
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):599-605. PubMed ID: 26176751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How do biosimilars sustain value, affordability, and access to oncology care?
    Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):327-329. PubMed ID: 32842809
    [No Abstract]   [Full Text] [Related]  

  • 16. Limits on Medicare's ability to control rising spending on cancer drugs.
    Bach PB
    N Engl J Med; 2009 Feb; 360(6):626-33. PubMed ID: 19176475
    [No Abstract]   [Full Text] [Related]  

  • 17. [Is the price of cancer drugs related to the cost of develo-pment and production or to the economic value of their clincal efficacy?].
    Russi A; Serena M; Palozzo AC
    Recenti Prog Med; 2016 Apr; 107(4):181-5. PubMed ID: 27093327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer drug prices and the free-market forces.
    Kantarjian H; Zwelling L
    Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
    [No Abstract]   [Full Text] [Related]  

  • 19. Can cancer care lead the way toward a value-based future?
    Macmillan K
    Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP377-SP378. PubMed ID: 31860249
    [No Abstract]   [Full Text] [Related]  

  • 20. The cost and burden of cancer in the European Union 1995-2014.
    Jönsson B; Hofmarcher T; Lindgren P; Wilking N
    Eur J Cancer; 2016 Oct; 66():162-70. PubMed ID: 27589247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.